Clinical Trials Logo

Filter by:
NCT ID: NCT05522998 Recruiting - Bariatric Surgery Clinical Trials

Efficacy and Safety of Ciprofol in Laparoscopic Sleeve Gastrectomy

Start date: January 1, 2023
Phase: Phase 4
Study type: Interventional

To evaluate the efficacy and safety of ciprofol for the induction of general anesthesia in obese patients undergoing laparoscopic sleeve gastrectomy. A randomized, parallel, propofol injection positive control study will be conducted to select obese patients who will undergo laparoscopic sleeve gastrectomy in the author's hospital. To evaluate the efficacy and safety, the main observation index, secondary observation indexes, safety evaluation indexes, and the incidence of postoperative adverse reactions will be recorded and compared between the two groups.

NCT ID: NCT05522985 Recruiting - Clinical trials for Head and Neck Squamous Cell Carcinoma

Neoadjuvant Chemotherapytreatment of Locally Advanced Head and Neck Squamous Cell Carcinoma

Start date: November 7, 2021
Phase: Phase 2
Study type: Interventional

The objective of research is to evaluate the efficacy and safety of treprizumab injection combined with AP regimen in the treatment of resectable locally advanced head and neck squamous cell carcinoma.122 patients were randomly divided into two groups: the test group (treprizumab injection combined with AP protocol) and the control group (TP protocol); The patients in both groups were treated with three cycles of induction therapy. After the induction therapy, the patients were evaluated and followed up with surgery.

NCT ID: NCT05522907 Not yet recruiting - Prostate Cancer Clinical Trials

Investigation of Tumor Microenvironment After CRPC Along With Before and After Neoadjuvant Therapy for Prostate Cancer

Start date: September 1, 2022
Phase:
Study type: Observational

In recent years, the clinical research of immunotherapy including PD-1 antibody and CD3 bispecific antibody in prostate cancer has been increasing day by day. The comparison with the analysis results of cancer tissues of advanced patients has important guiding significance for the application of these new treatment methods. In a retrospective study, investigators plan to perform multi-omics analysis (including whole exome, RNAseq), immune cell characterization, and biopsy samples from prostate cancer primary biopsy, ADT neoadjuvant, and CRPC biopsy samples in the biobank. Protein and prostate cancer-specific antigen expression were analyzed by immunohistochemistry. The following questions are answered by comparing samples from different treatment stages in early and advanced stages: 1. Whether the immune environment becomes "cold" in the advanced stage; 2. Which immune cell populations have changed significantly; 3. Is the inhibitory immune microenvironment related to genes Mutations or suppressive immune cell populations.

NCT ID: NCT05522738 Recruiting - Clinical trials for Metastatic Colorectal Cancer

Safety and Efficacy of Fruquintinib+FOLFIRI in RAS-mutated Metastatic Colorectal Cancer

Start date: August 10, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

Molecular subtypes make difference on clinicopathologic features and response to chemotherapy and targeted agents as well as prognosis. RAS mutation status, which accounting for approximately 35% to 40% of colorectal cancer patients, is an important factor considered in the standard of care for colorectal cancer. For RAS-mutated patients, no targeted driver gene drugs have been approved, and their treatment is based on the anti-VEGF/VEGFR pathway, and corresponding targeted drugs such as bevacizumab, aflibercept, and ramucirumab have also been successfully marketed for the treatment of CRC. For RAS mutant metastatic colorectal cancer, the commonly used first-line treatment regimen is bevacizumab combined with chemotherapy, which is shown in previous studiesthat the PFS of 1st-line is about 10 months; the standard regimen of second-line treatment is FOLFIRI ± bevacizumab, which is shown in previous study that the 2nd-line PFS is about 5 months with ORR 4%. There are a lot of unmet medical needs to improve the clinical efficacy in secondline-treatment of RAS-mutant patients.

NCT ID: NCT05522634 Not yet recruiting - Clinical trials for Premature Ovarian Failure

A Clinical Study of Chinese Herbal Compound TJAOA101 in the Treatment of Premature Ovarian Insufficiency

Start date: November 1, 2022
Phase: Early Phase 1
Study type: Interventional

Premature ovarian insufficiency (POI) seriously affects the physical and mental health of women. Nowadays, Chinese herbs have huge appeal and potential in treating POI. We have created a new Chinese herbal combination TJAOA101, whereas its safety and efficacy still need to be validated. Hence, we will perform a population-based, multicenter study to confirm the safety and efficacy of TJAOA101 in therapy of POI. We aim to provide a solid evidence for TCM in therapy of POI.

NCT ID: NCT05522582 Recruiting - Solid Tumors Clinical Trials

Methotrexate Combined With Immunotherapy During Radiotherapy for Solid Tumors

Start date: November 15, 2021
Phase: Phase 2
Study type: Interventional

Immune checkpoint inhibitors, such as programmed death 1 (PD-1) and programmed cell death-Ligand 1 (PD-L1), offer new approaches for systemic treatment of tumors, but clinical efficacy remains limited. Previous studies by our team have found that methotrexate can activate anti-tumor immunity. The discovery of a new effect of this drug will improve tumor response to immunotherapy and prognosis of patients.

NCT ID: NCT05522504 Active, not recruiting - Gout Flare Clinical Trials

Distribution of Immune Cells and Their Subtypes in Peripheral Blood of Gout

Start date: September 15, 2022
Phase:
Study type: Observational

The purpose of this study is to evaluate whether immune cells and their subtypes in peripheral blood affects the asymptomatic hyperuricemia, gout flare, intercritical gout and advanced gout.

NCT ID: NCT05522465 Recruiting - Clinical trials for Immune Thrombocytopenia

Short-course High-dose Prednisone and Dexamethasone in Children With ITP

Start date: October 11, 2022
Phase: Phase 4
Study type: Interventional

Comparison of the efficacy and safety of short-course high-dose prednisone and dexamethasone in the treatment of children with newly diagnosed immune thrombocytopenia (ITP)

NCT ID: NCT05522439 Active, not recruiting - Clinical trials for Asthma With Eosinophilic Phenotype

A Study to Evaluate the Pharmacodynamic, Efficacy and Safety of SHR-1703 in Asthma Patients With Eosinophil Phenotype

Start date: December 22, 2022
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the Pharmacodynamic, Efficacy and Safety of SHR-1703 in Asthma Patients with Eosinophil Phenotype.

NCT ID: NCT05522400 Recruiting - Clinical trials for Rehabilitation Exercise of ICU Patients

Development and Application of Virtual Reality (VR) and Human Computer Interaction System in the ICU Patients

Start date: May 1, 2021
Phase: N/A
Study type: Interventional

By developing of VR and human computer interaction system of early rehabilitation exercise for ICU patients, this project aims to construct virtual scenes and realize the interaction between ICU patients and virtual scenes during active rehabilitation training for critically ill patients in long-term bed. This project can increase the patient's willingness to exercise rehabilitation, improve the training effect and improve clinical outcomes in critically ill patients.